THERAPEUTIC EPIGENETIC ENHANCEMENT OF THE INNATE IMMUNITY TO EFFECTIVELY COMBAT ANTIMICROBIAL RESISTANCE [IN-ARMOR]core
IN-ARMOR · Horizon Europe grant · 2023-05-01–2027-04-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-HLTH-2022-DISEASE-06-two-stage · scheme HORIZON-RIA · topic HORIZON-HLTH-2022-DISEASE-06-02-two-stage. CORDIS record →
Objective
Antimicrobial resistance (AMR) & multi-drug resistance, whereby pathogens evolve to resist antibiotic drugs, is designated by WHO one of the top 10 health threats of our time and is a top 3 priority health threat requiring EU level coordination. AMR was estimated to be linked to 4.95 million deaths in 2019. The next global pandemic could be a multi-drug resistant bacterium, or emergence of ‘pan-drug’ resistant strains (resistant to all existing drugs). Alternative therapeutic approaches are proving to be expensive and slow to develop, whilst also facing the risk of evolving strains. The innate immunity presents the strongest potential to tackle AMR as it can generate antimicrobial molecules and proteins that directly inhibit microbial survival. Inducing such proteins has shown effective antimicrobial activity against bacteria, viruses, fungi & protozoa. Building on this approach, leading professors and researchers from 9 Universities and research institutes are collaborating with 7 medical and industry partners representing 9 EU countries to introduce a novel class of immune system inducers able to enhance the body’s own innate microbial defence mechanisms to combat AMR and reduce incidence of the 13 listed most dangerous infections (including 2 of the top 3 priority-1 infections).IN-ARMOR will optimise an already developed drug platform using Computer Aided Drug Design, and in-silico approaches, in tandem with a nanotech-based drug delivery system for the first target indication. The developed therapy will be pre-clinically validated for safety and efficacy in-vitro and in vivo to complete all investigational Medicinal Product requirements.Upon completion, IN-ARMOR will be prepared for clinical validation. Upon commercialisation, IN-AMOR could potentially save more 4Mn lives worldwide and result in the significant burden reduction of antibiotic development with long-term cost reduction impact of €107Bn, whilst reducing the global disease burden by 96.84Mn DAL
Beneficiaries (18)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| HASKOLI ISLANDS | IS | coordinator | €1,072,500 | |
| ACONDICIONAMIENTO TARRASENSE ASSOCIACION | ES | participant | €823,610 | |
| AKTHELIA EHF. | IS | participant | €605,750 | Yes |
| RIJKSUNIVERSITEIT GRONINGEN | NL | participant | €390,562 | |
| UNIVERSIDAD DE VIGO | ES | participant | €390,000 | |
| JYVASKYLAN YLIOPISTO | FI | participant | €368,344 | |
| SERVICIO MADRILENO DE SALUD | ES | participant | €348,518 | |
| NUVISAN FRANCE SARL | FR | participant | €348,000 | |
| OBELIS SA | BE | participant | €338,625 | Yes |
| VIBIOSPHEN | FR | participant | €321,758 | Yes |
| KAROLINSKA INSTITUTET | SE | participant | €308,100 | |
| BIOKERALTY RESEARCH INSTITUTE AIE | ES | participant | €285,250 | |
| BETTHERA SRO | CZ | participant | €145,625 | Yes |
| INSPIRALIA SOCIEDAD LIMITADA | ES | participant | €109,831 | Yes |
| ENAMINE LIMITED LIABILITY COMPANY,RESEARCH AND PRODUCTION ENTERPRISE | UA | participant | €100,000 | Yes |
| TAMPEREEN KORKEAKOULUSAATIO SR | FI | participant | €42,500 | |
| FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO RAMON Y CAJAL | ES | thirdParty | €0 | |
| NUVISAN ICB GMBH | DE | participant | €0 |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.